🎯 check Dabrafenib (GSK2118436) product page
Dabrafenib is a potent BRAF inhibitor. It affects MAPK/ERK signaling by binding to BRAF, inhibiting tumor cell proliferation.
Dabrafenib (GSK2118436) Mechanism of Action: BRAF Inhibition in Melanocyte Research
Dabrafenib (GSK2118436) MOA：Targeting BRAF/MAPK Pathway for Melanoma
Jump to:
- Dabrafenib (GSK2118436): Selectivity & Specificity
- Dabrafenib (GSK2118436) Working Concentration | Cell Culture | Treatment
- Dabrafenib (GSK2118436) Solubility in DMSO
- Dabrafenib (GSK2118436) Combination Database
- Dabrafenib (GSK2118436) Molecular Weight | Chemical Structure | Stock Solution
- Dabrafenib (GSK2118436) IC50 for Cell-based and Cell-free Assays
- Dabrafenib (GSK2118436) Sigma (AMBH47A8ED73)? Try a better option.
- Dabrafenib (GSK2118436) MedChemExpress (HY-14660)? Try a better option.
- Dabrafenib (GSK2118436) Cayman (16989)? Try a better option.
- Dabrafenib (GSK2118436) Abmole (M1988)? Try a better option.
- Dabrafenib (GSK2118436) Cell Signaling Technology (91942)? Try a better option.
- Dabrafenib (GSK2118436) SDS｜MSDS
- Dabrafenib (GSK2118436) in Melanoma
- Dabrafenib (GSK2118436) in Non-Small Cell Lung Cancer
- Dabrafenib (GSK2118436) in Solid Tumors